These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27766582)

  • 1. Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.
    Dhoot DS; Avery RL
    Curr Diab Rep; 2016 Dec; 16(12):122. PubMed ID: 27766582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
    Ajlan RS; Silva PS; Sun JK
    Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis.
    Xie X; Lian C; Zhang Z; Feng M; Wang W; Yuan X; Shi Y; Liu T
    Front Endocrinol (Lausanne); 2023; 14():1144422. PubMed ID: 37260449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor and diabetic macular edema.
    Lally DR; Shah CP; Heier JS
    Surv Ophthalmol; 2016; 61(6):759-768. PubMed ID: 27045225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving strategies in the management of diabetic macular edema: clinical trials and current management.
    Thomas BJ; Shienbaum G; Boyer DS; Flynn HW
    Can J Ophthalmol; 2013 Feb; 48(1):22-30. PubMed ID: 23419295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
    Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
    JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for anti-VEGF treatment of diabetic macular edema.
    Bandello F; Berchicci L; La Spina C; Battaglia Parodi M; Iacono P
    Ophthalmic Res; 2012; 48 Suppl 1():16-20. PubMed ID: 22907145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management paradigms for diabetic macular edema.
    Mitchell P; Wong TY;
    Am J Ophthalmol; 2014 Mar; 157(3):505-13.e1-8. PubMed ID: 24269850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.
    Evoy KE; Abel SR
    Ann Pharmacother; 2013 Jun; 47(6):811-8. PubMed ID: 23656749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current intravitreal pharmacologic therapies for diabetic macular edema.
    Colucciello M
    Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Vascular Endothelial Growth Factor Injections: The New Standard of Care in Proliferative Diabetic Retinopathy?
    Li X; Zarbin MA; Bhagat N
    Dev Ophthalmol; 2017; 60():131-142. PubMed ID: 28427072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic macular edema.
    Lang GE
    Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Hirabayashi K; Nagaoka T; Takamura Y; Sugimoto M; Murata T
    Jpn J Ophthalmol; 2017 Jan; 61(1):51-60. PubMed ID: 27730425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
    Giuliari GP; Guel DA; Cortez MA; Cortez RT
    Can J Ophthalmol; 2010 Oct; 45(5):501-8. PubMed ID: 20648074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.